Skip to main content
. 2019 Jul 26;98(30):e16624. doi: 10.1097/MD.0000000000016624

Figure 5.

Figure 5

Subgroup analysis of the prognostic value of SLC16A12 mRNA in patients ccRCC. (A, B) The decreased expression of SLC16A12 mRNA was not associated with OS (P = .104) in patients with TNM stage I and II, whereas in patients with TNM stage III and IV, the OS was significantly lower in patients with low SLC16A12 mRNA expression compared with high expression group (P < .001). (C, D) Subgroup analysis by pathological grade showed that the expression of SLC16A12 mRNA was not associated with OS in patients with grade I and grade II (P = .102), but in the poorly differentiated group, including grade III and IV group, the OS of patients with SLC16A12 mRNA low expression group was notably lower than that of high expression group (P < .001). The SLC16A12 mRNA expression levels were divided at a cutoff point of 50%. OS = overall survival.